Dusquetide

Unassigned

New Medicines

Severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy

Information

New molecular entity
Soligenix
Soligenix

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
May 20Soligenix announces that due to the uncertainty surrounding the coronavirus pandemic, they will enrol 25 additional patients into the PIII DOM–INNATE (NCT03237325) study in order to maintain the statistical integrity of the trial. Therefore, the target to complete enrolment and provide top-line results is being revised to Q4 2020; however, this will remain dependent on the medical and logistical challenges caused by the coronavirus showing a reasonable level of improvement in the relative near-term [12]

Category

Immunomodulator: a synthetic 5-amino acid peptide modulating the regulatory protein p62 (sequestosome-1; SQSTM1), thus enhancing activity of the innate immune system; modulates inflammation healing.
Oral mucositis affects almost all patients receiving radiotherapy for head and neck cancer, with or without chemotherapy, and for some it is the most distressing part of their treatment [3]. If severe, it causes inability to eat or drink, leading to the need for tube feeding, and it predisposes to infection that can progress to sepsis [4].
Severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy
Intravenous

Further information

Yes
To be confirmed